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Abstract
Background: Severe lower respiratory tract infections in pediatric populations result in millions of
hospitalizations worldwide. Some children experience recurrent symptoms and progressive episodes multiple
times a year. Azithromycin has demonstrated not only antimicrobial but also potential antiviral and anti-
inflammatory properties. Can azithromycin decrease disease severity or recurrence in pediatric patients with
debilitating chronic respiratory tract symptoms?
Methods: Exhaustive search of available medical literature was performed using MEDLINE-Ovid, Web of
Science, and CINAHL. The search terms azithromycin, respiratory tract infection, lower respiratory tract,
disease progression, and recurrence were used. Studies were limited to children, age 0 to 18, and randomized
control trials. Articles were assessed for quality using the Grading of Recommendations, Assessment,
Development, and Evaluation (GRADE) criteria.
Results: Two articles met eligibility criteria. The studies were randomized control trials evaluating
azithromycin and its effect on respiratory tract infections. They both demonstrated improved outcomes in
symptom severity and progression. The overall quality of both studies was moderate with room for future
improvement.
Conclusion: Azithromycin is an appropriate treatment option to consider when evaluating an effective
treatment plan for pediatric populations with multiple severe recurrent respiratory tract symptoms. It is
important to tailor each treatment plan with patient response and judiciously utilize antibiotics. The most
appropriate timeframe and dose of therapy is still to be determined.
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Abstract  
Background: Severe lower respiratory tract infections in pediatric populations result in 
millions of hospitalizations worldwide. Some children experience recurrent symptoms and 
progressive episodes multiple times a year. Azithromycin has demonstrated not only 
antimicrobial but also potential antiviral and anti-inflammatory properties. Can 
azithromycin decrease disease severity or recurrence in pediatric patients with debilitating 
chronic respiratory tract symptoms? 
Methods:  Exhaustive search of available medical literature was performed using 
MEDLINE-Ovid, Web of Science, and CINAHL. The search terms azithromycin, respiratory 
tract infection, lower respiratory tract, disease progression, and recurrence were used. 
Studies were limited to children, age 0 to 18, and randomized control trials. Articles were 
assessed for quality using the Grading of Recommendations, Assessment, Development, 
and Evaluation (GRADE) criteria. 
Results:  Two articles met eligibility criteria. The studies were randomized control trials 
evaluating azithromycin and its effect on respiratory tract infections. They both 
demonstrated improved outcomes in symptom severity and progression. The overall 
quality of both studies was moderate with room for future improvement.   
Conclusion: Azithromycin is an appropriate treatment option to consider when evaluating 
an effective treatment plan for pediatric populations with multiple severe recurrent 
respiratory tract symptoms. It is important to tailor each treatment plan with patient 
response and judiciously utilize antibiotics. The most appropriate timeframe and dose of 
therapy is still to be determined.    
Keywords:  azithromycin, respiratory tract infection, lower respiratory tract, disease 
progression, recurrence 
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BACKGROUND 
Pediatric populations are exposed to a variety of viruses and bacteria in everyday 
life. It is estimated that children under the age of five were admitted to the hospital for 
severe lower respiratory tract infections (LRTIs) 12 million times worldwide in 2010. In 
the United States alone 6 out of every 100 children were hospitalized for a severe LRTI.1 
Most of these incidences are acute respiratory tract infections. Unfortunately, some 
children experience severe, recurrent respiratory tract symptoms throughout childhood. 
These recurrent symptoms can progress to severe infections and pose a significant area of 
concern for both patients and caregivers.  
 The complete etiology of recurrent respiratory tract symptoms is unclear. Most 
suggest that early viral infections are at fault for childhood wheezing and respiratory 
symptoms,2 while others find bacterial infections to be equally related to episodes.3 
Regardless of etiology, morbidity and mortality exist. With recurrent symptoms children 
are at increased risk of respiratory issues in the future,4 missed school days, and 
subsequent sequela. Karmaus et al5 furthermore demonstrated that children with 
recurrent LRTIs were 4 times more likely to develop asthma in the first decade of life. 
Recurrent symptoms also increase healthcare utilization through primary care provider, 
emergency room, and urgent care visits. New treatment options hold promise in 
addressing concerns of recurrent respiratory tract symptoms.  
 One treatment option of interest is the antibiotic azithromycin. While azithromycin 
is widely known for its coverage of atypical bacteria and respiratory concerns, current 
research is also looking at it’s anti-inflammatory6,7 and antiviral8 properties as well. 
Azithromycin is generally well tolerated and cost effective. In pediatric populations treated 
with azithromycin, 6-27% report adverse reactions. These reactions are most often 
gastrointestinal and include nausea, vomiting, diarrhea, and abdominal cramps. Serious 
concerns such as Stevens-Johnson, Schonlein-Henoch, and Churg-Strauss syndromes are 
rare.9 According to Tarascon,10 the average cost of treatment is $25-$49 per episode. These 
characteristics make azithromycin an ideal theoretical treatment option to mitigate some 
of the difficulties surrounding recurrent respiratory symptoms in children.  
 Much research has been done on azithromycin with regards to acute respiratory 
conditions11,12 and chronic conditions like cystic fibrosis.13 This review looks to determine 
what effect azithromycin can have on pediatric patients who suffer numerous episodes of 
progressive respiratory tract symptoms throughout the year and who are generally healthy 
at baseline. Ultimately, can azithromycin decrease disease severity or recurrence in 
pediatric patients with chronic lower respiratory tract symptoms? 
METHODS  
An exhaustive literature search using MEDLINE-Ovid, Web of Science, and CINAHL 
was conducted. The search terms azithromycin, respiratory tract infection, lower 
respiratory tract, disease progression, and recurrence were used. Studies were limited to 
children, age 0 to 18, and randomized control trials. Studies looking at defined recurrent 
respiratory tract symptoms were identified and chronic asthma was excluded. Articles 
were assessed for quality using the Grading of Recommendations, Assessment, 
Development, and Evaluation (GRADE) criteria.14   
RESULTS  
The initial search was completed in MEDLINE-Ovid. This resulted in 30 articles. Web 
of Science resulted in another six articles and CINAHL found one. Duplicates were removed 
and eligibility criteria applied. Two articles15,16 were selected and included for review. Per 
inclusion criteria, both are randomized control trials evaluating azithromycin and 
recurrent respiratory tract infections. See Table I. 
Bacharier et al 
 This most recent study15 looked at early administration of azithromycin and 
evaluated its ability to prevent progression to severe lower respiratory tract infections. 
This randomized, double blinded control trial was conducted between April 2011 and 
December 2014. It focused on preschool children with a history of recurrent lower 
respiratory tract infections. This history included severe wheezing with LRTI signs and 
symptoms that required one of the following: an unscheduled visit to a primary care 
provider (PCP), urgent care, or emergency room or systemic corticosteroids. The primary 
outcome was whether or not azithromycin administered early in the development of LRTI 
symptoms could decrease the severity of the LRTI.15 
 The study’s 607 participants were chosen from nine US medical facilities. All were 
between the ages of 12 and 71 months. Each was given an individualized action plan and 
parents were instructed to provide treatment at the first signs and symptoms of a LRTI. 
Computer generated randomization assigned 307 participants to the azithromycin 
treatment group and the matching placebo group had 300. The azithromycin was dosed at 
12mg/kg/d for 5 days. Both groups received symptomatic care of albuterol 4 times per day 
during the first 48 hours and as needed after.15  
 Throughout the course of the trial 443 of the participants had 937 LRTI, 473 in the 
azithromycin group and 464 in the placebo group. There were 164 participants who did 
not experience a LRTI, 84 in the azithromycin group and 80 in the placebo group. There 
were 433 who were treated during the first LRTI, 293 for a second, 152 for a third, and 49 
for a fourth. A total of 214 participants were lost to follow-up or early termination criteria. 
The hazards ratio was 0.64 with a 95% confidence ratio of 0.41-0.98, P=0.04. The number 
need to treat was dependent on the number of recurrent LRTI experiences by the child. In 
patients with one LRTI the NNT was 33, with two LRTIs the NNT was 14, with three it was 
10, and with four it was 7. Symptoms scores for participants treated with azithromycin 
during a LRTI that proceeded to severe were also less when compared to placebo. The 
results indicate that the azithromycin group had a decreased risk of progressing to a severe 
LRTI when compared to placebo and were more likely to respond to azithromycin the more 
recurrent their LRTI symptoms. There was no difference in time to second RTI between the 
two treatment groups.15 See Table II. 
 One major limitation of the study was the fact that the randomization period was 
extended from 12 to 18 months and up to four LRTIs. This was done as the result of a mild 
respiratory illness season the first year. Data may be different if all participants were 
followed for the 78 weeks. Another limitation is that a participant met exclusion criteria 
after one severe LRTI and was subsequently removed from the trial. Therefore, data cannot 
be applied to recurrent LRTI after a severe LRTI. It is also important to note that the 
treatment was applied during early stages of the disease progress and not once full severe 
LRTI symptoms were present.15  
Esposito et al 
 The second study16 looked at recurrent respiratory tract infections (RRTIs) to 
determine if azithromycin could decrease disease progression and limit recurrence. They 
also looked to see if patients age 1-14 years had an increased incidence of Mycoplasma 
pneumoniae or Chlamydia pneumoniae infections. This blinded, randomized study was 
done between November 2000 and March 2002 at the University of Milan, Italy. A 
recurrent infection was defined as eight or more infections per year in children <3 years 
old or six or more in children ≥ 3 years old.16 
 In this study 352 participants with a history of recurrent RRTIs were enrolled. A 
computer list randomized the patients and the azithromycin group of 177 participants was 
given 10mg/kg/d for 3d/wk over 3 weeks. There were 175 participants in the symptom 
treatment group alone. Both groups received symptomatic treatment with acetaminophen, 
10mg/kg/dose. Symptom reports were kept by all participants, and follow-up was 
recorded at 1 month and 6 months. Clinical success was determined by complete resolution 
of symptoms at 1 month with no recurrence of symptoms, or no more than two relapses of 
symptoms after the 6 month mark.16  
 Of the 177 participants in the azithromycin group, 171 obtained treatment success. 
All of the 76 participants who tested positive for Mycoplasma pneumoniae or Chlamydia 
pneumoniae infections and were treated with azithromycin also obtained clinical success. 
In the other group 144 out of 175 participants achieved clinical success. When looking at 
overall clinical success the NNT was 6. RRR was 0.81 with a 95% CI of 0.55 to 0.92. Also of 
importance is the 6-month clinical success. In the azithromycin group, 108 out of 170 
achieved clinical success when compared to 88 out of 169 at the 6 months’ follow-up in the 
symptoms only group. The NNT for long term clinical success was 8.16 See Table II. 
DISCUSSION 
Treatment options for recurrent respiratory tract symptoms have often relied 
heavily on symptomatic care and the assumption of viral etiology. While treatment is highly 
patient response dependent, current therapy includes a combination of inhaled short 
acting beta2-agonists, inhaled corticosteroids, and systemic steroids. While the overall 
quality of these studies is moderate, clinicians can consider adding azithromycin as an 
option in treating pediatric patients with severe recurrent respiratory tract symptoms. As 
previously discussed, azithromycin is well tolerated by most pediatric patients and is 
generally inexpensive. This is especially true when comparing the cost of one course of 
antibiotics to the cost of hospitalization for a severe LRTI. Regardless, it is important to 
judiciously consider initiation of antibiotics and compare the risks to benefits of antibiotic 
therapy. 
The two studies15,16 clearly demonstrate an improvement in the azithromycin 
treatment group. Bacharier et al15 showed that as the number of azithromycin-treated 
LRTIs increased, the NNT to in order to prevent a severe LRTI decreased. This 
demonstrates a dose-response gradient of sorts. Moreover, there was a decrease in the 
overall symptom score of the treatment group when compared to placebo. However, they 
did not demonstrate a decrease in the time or recurrence to second LRTI. While suggesting 
azithromycin as an option in the truly recurrent severe patient with LRT symptoms, 
caution about the potential for increased microbial resistance with widespread 
prophylactic treatment must be considered.15 In Esposito et al16 clinical success with 
resolution of symptoms in one month was negligible between the treatment groups. As 
expected there was an increased symptom resolution response in the azithromycin group 
with confirmed bacterial infections. However, clinical success at the 6-month mark in the 
azithromycin group was increased regardless of symptom etiology.16  
When comparing the two studies15,16 it is important to consider the differences that 
limit their complete comparison. One big difference is the treatment dose of azithromycin. 
In Bacharier et al,15 they used a shorter course of therapy, 12 mg/kg/d, over five days, 
while Esposito et al16 chose a longer duration of treatment, 10mg/kg/d for 3 days over 3 
weeks. It is difficult to suggest what an ideal azithromycin dose or course would entail. 
Another key difference in reviewing the studies is the duration and structure of the study 
itself. Bacharier et al,15 tracked and treated a cohort of patients with recurrent LRTI over 
52 to 78 weeks. They recorded and addressed each episode with an emphasis on early 
intervention, progression to severe, and time to next recurrence. Esposito et al,16 identified 
pediatric patients with a history of RRTI who presented with acute respiratory tract 
symptoms. They treated based on treatment group regardless of current severity and 
tracked resolution of symptoms or clinical success at 1 and 6 months. Also, they included 
no placebo or blinding for the patients or caregivers. There was a wide range of RRTIs 
included in this study with a broad definition of clinical success.16  
 Appropriate use of azithromycin in pediatric lower respiratory tract symptoms is 
still an evolving topic, thus continued research in this area should be pursued. The most 
important area is proper identification in which pediatric patients would benefit most from 
azithromycin initiation. This must be compared to changes in bacterial resistance and 
subsequent sequela. Another area includes an appropriate dose and time frame for 
administration of antibiotics with symptomatic care. It is also still to be determined the 
true mechanism of action for azithromycin effectiveness in respiratory tract infections.  
CONCLUSION  
Azithromycin is an appropriate treatment option to consider when treating 
pediatric patients with severe recurrent respiratory tract symptoms. While the benefits of 
azithromycin are strongly demonstrated, it is important to consider concerns regarding 
microbial resistance. Further research in this area is necessary before widespread 
prophylactic treatment of severe LRTI for the general pediatric population is 
recommended. When identifying the ideal patient to treat with azithromycin, it is 
important to note that these patients are generally healthy at baseline with multiple 
recurrent episodes of debilitating symptoms throughout the year. In this specific patient 
population early administration of azithromycin can ideally prevent the progression to 
severe infection. This decreases symptom severity, disease burden, and childhood 
morbidity.  
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Table I. Characteristics of Reviewed Studies 
 
Study Design 
Downgrade Criteria 
Upgrade 
Criteria 
Quality 
Limitation Indirectness Inconsistency Imprecision 
Publication 
bias 
Bacharier 
et al15 
RCT 
Not 
Serious 
Not Serious Not Serious Not Serious Likelya 
Dose-
Response 
Gradientb 
High 
Esposito 
et al16 
RCT Seriousc Not Serious Not Serious Not Serious Likelya None Low 
a Small number of studies  
b NNT decreased as the doses increased 
c Lack of blinding of patients and caregivers, no placebo 
 
Table II. Summary of Findings 
 
Study 
Treatment 
Group 
Comparison 
Patient 
Population 
Study Length 
NNT 
Acute 
NNT 
Recurrence 
Bacharier et 
al15 
Azithromycin 
12mg/kg/d x 
5days 
 
N=307 
Placebo 
 
N = 300 
12 to 71 
months olds 
with 
recurrent 
LRTI 
12-18 month 
period 
1 LRTI = 33 
2 LRTI = 14 
3 LRTI = 10 
4 LRTI = 7a 
No changeb 
Esposito et al16 
Azithromycin 
10mg/kg/d 
for 3 
days/week 
for 3 weeks 
 
N=177 
None 
 
N=175 
1 to 14 year 
olds with 
recurrent 
RRTIc 
6 months NNT= 6d 
NNT = 8 
 
Clinical success 
at 6 monthse 
a Evaluated as did not progress to severe  
b Author reports deference in time to second LRTI negligible, no data provided 
c Excluded AOM, community acquired pneumonia, streptococcal pharyngitis at enrollment 
d Symptom resolution without relapse at one-month 
e Author defined clinical success at 6 months if ≤ 2 symptom relapses 
 
 
